Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Mediation between Bayer, plaintiffs seeks to clarify all justified claims: U.S. mediator

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/13/2019 | 10:04am EST
FILE PHOTO: Logo of Bayer AG at a plant of the German pharmaceutical and chemical maker in Wuppertal

Mediation between Bayer and plaintiffs in the United States aims to clarify all justified claims related to Roundup herbicide both at the national and state level, mediator Ken Feinberg told a German magazine.

"The mediation is going slowly but steadily," Wirtschaftswoche on Wednesday quoted Feinberg as saying.

Bayer is trying to reach a settlement after earlier court rulings against it. The German drugs and pesticides maker, which acquired Roundup and other glyphosate-based weed killers as part of its $63 billion takeover of Monsanto last year, faces potentially heavy litigation costs as plaintiffs claim Roundup causes cancer, something Bayer disputes.

(Reporting by Riham Alkousaa; Editing by Michelle Martin)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
12/06BAYER : to Hold Settlement Talks for Some Glyphosate Suits --Reuters
DJ
12/06BAYER : reaches agreement to postpone more glyphosate lawsuits for settlement ta..
RE
12/04CAPGEMINI : Inks IT Deal With Bayer Worth More Than EUR1 Billion
DJ
12/02MACQUARIE INFRASTRUCTURE : Bayer completes sale of Currenta stake to Macquarie I..
AQ
11/29MACQUARIE INFRASTRUCTURE : Bayer completes sale of Currenta stake to Macquarie I..
AQ
11/29BAYER : completes sale of Currenta stake to Macquarie Infrastructure and Real As..
PU
11/29BAYER AKTIENGESELLSCHAFT : Release according to Article 41 of the WpHG [the Germ..
EQ
11/27Thailand reverses ban of chemicals use in pesticides
RE
11/27BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
EQ
11/26Mass-Tort Machine Powers Wave of Roundup Lawsuits -2-
DJ
More news
Financials (EUR)
Sales 2019 44 091 M
EBIT 2019 7 725 M
Net income 2019 2 957 M
Debt 2019 36 698 M
Yield 2019 4,11%
P/E ratio 2019 21,8x
P/E ratio 2020 13,2x
EV / Sales2019 2,37x
EV / Sales2020 2,16x
Capitalization 67 964 M
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 80,44  €
Last Close Price 69,18  €
Spread / Highest target 77,8%
Spread / Average Target 16,3%
Spread / Lowest Target -44,0%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG14.23%75 247
JOHNSON & JOHNSON8.14%367 304
ROCHE HOLDING AG25.10%263 429
MERCK AND COMPANY16.15%225 956
PFIZER-12.88%210 463
NOVARTIS21.74%207 450